NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neogenomics (NEO) PT Lowered to $17 at BTIG
February 19, 2025 2:57 PM ESTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Shares of NEO have pulled back by ~30% following the (still surprising) news last month that the company's turnaround specialist and CEO, Chris Smith, will leave both the CEO seat and the... More
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
February 19, 2025 8:05 AM ESTMorgan Stanley analyst Tejas Savant lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Equalweight rating.
The analyst comments "Surprising albeit small miss on pharma budget flush spoils long track record of beats/raises; 25 guide/LRP in line w/ Jan prelim;... More
Neogenomics (NEO) PT Lowered to $18 at Needham
February 18, 2025 4:01 PM ESTNeedham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "NEO's 4Q24 revenue missed, while its EBITDA beat consensus. Management reiterated their 2025 revenue and EBITDA guidance. Revenue growth was... More
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)
February 18, 2025 8:12 AM ESTRaymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).
The analyst comments "Quick take: This morning NeoGenomics reported 4Q results with the top line roughly 70 bp below consensus and nearly 200 bp below our view. With Clinical Services and Advanced Diagnostics now combined into one segment, visibility is lessened, but we estimate the former roughly matched consensus while... More
